Data are provided by many contributors through the the WHO Clinical data platform and are not necessarily representative. To become a contributor, please see the terms of use and register here.

Total cases

86

Confirmed cases

44

Total PLWH

11

Women

38.4%

Children below 5

14.0%

Total deaths

1

The map below is just a proof of concept. Can be adjusted once/if we have data at the regional level.

Geospatial distribution
Cases reported
Mirror plots
Chronic conditions
Variable Sample size Prevalence pct Frequency
HIV (Human Immunodeficiency Virus) 86 12.8% 11 / 86
Hypertension 86 4.7% 4 / 86
Current new STI (Sexually Transmitted Infection) diagnosis? 86 2.3% 2 / 86
Syphilis 2 100.0% 2 / 2
Current alcohol use disorder 86 1.2% 1 / 86
Immunosuppressive condition 86 1.2% 1 / 86
Chronic heart disease 86 0.0% 0 / 86
Chronic lung disease 86 0.0% 0 / 86
Chronic kidney disease 86 0.0% 0 / 86
Chronic liver disease 86 0.0% 0 / 86
Chronic neurologic condition 86 0.0% 0 / 86
Previous COVID-19 infection 86 0.0% 0 / 86
Diabetes 86 0.0% 0 / 86
Currently smokes tobacco 86 0.0% 0 / 86
Skin Conditions 86 0.0% 0 / 86
Tuberculosis (previous) 86 0.0% 0 / 86
Tuberculosis (active) 86 0.0% 0 / 86
Asplenia 86 0.0% 0 / 86
Cancer 86 0.0% 0 / 86
N. gonorrhoeae 2 0.0% 0 / 2
HSV 2 0.0% 0 / 2
Chlamydia trachomatis 2 0.0% 0 / 2
HPV 2 0.0% 0 / 2
AIDS - defining illness 10 0.0% 0 / 10

Source: WHO
Complications
Variable Sample size Prevalence pct Frequency
Cellulitis 81 24.7% 20 / 81
Bacteraemia 81 11.1% 9 / 81
Abscess 81 6.2% 5 / 81
Anaemia 81 3.7% 3 / 81
Bacterial Pneumonia 81 3.7% 3 / 81
Sepsis 81 2.5% 2 / 81
Viral Pneumonia / Pneumonitis 81 2.5% 2 / 81
Ocular Complications 81 2.5% 2 / 81
Shock 81 1.2% 1 / 81
Encephalitis / Meningitis 81 1.2% 1 / 81
Bleeding Disorder 81 1.2% 1 / 81
Cardiac Arrest 81 1.2% 1 / 81
Cardiac Arrhythmia 81 1.2% 1 / 81
Cardiomyopathy 81 1.2% 1 / 81
Myocarditis / Pericarditis 81 1.2% 1 / 81
Acute Respiratory Distress Syndrome (Ards) 81 1.2% 1 / 81
Urinary Retention 81 1.2% 1 / 81
Necrotizing Infection 81 1.2% 1 / 81
Seizure 81 0.0% 0 / 81
Stroke / Cerebrovascular Accident 81 0.0% 0 / 81
Guillain-Barré Syndrome 81 0.0% 0 / 81
Acute Renal Injury / Acute Renal Failure 81 0.0% 0 / 81
Pancreatitis 81 0.0% 0 / 81
Liver Dysfunction 81 0.0% 0 / 81
Proctitis 81 0.0% 0 / 81
Rectal Urgency 81 0.0% 0 / 81
Rectal Pain 81 0.0% 0 / 81

Source: WHO
Body map of lesions at admission
Prevalence of lesions at admission
Variable Sample size Prevalence pct Frequency
Upper limb 85 83.5% 71/85
Chest and abdomen 85 81.2% 69/85
Head and neck 85 78.8% 67/85
Lower limb 85 75.3% 64/85
Back 85 74.1% 63/85
Genitals 85 49.4% 42/85
Mouth 84 25.0% 21/84

Source: WHO
Type of lesions
Variable Sample size Prevalence pct Frequency
Papule 86 77.9% 67/86
Macule 86 58.1% 50/86
Small pustule 86 38.4% 33/86
Crusting of a mature lesion 86 34.9% 30/86
Umbilicated pustule 86 33.7% 29/86
Ulcerated lesion 86 31.4% 27/86
Early vesicle 86 30.2% 26/86
Partially removed scab 86 17.4% 15/86

Source: WHO
Reported symptoms
Symptoms at admission
Variable Sample size Prevalence pct Frequency
Fever 85 84.7% 72 / 85
Headache 86 64.0% 55 / 86
Pruritis/itching 85 63.5% 54 / 85
Muscle pain or aching 86 54.7% 47 / 86
Fatigue or malaise 86 53.5% 46 / 86
Sore throat 86 38.4% 33 / 86
Joint pain or aching 86 30.2% 26 / 86
Pain in mouth 86 26.7% 23 / 86
Swallowing problem 86 26.7% 23 / 86
Painful swallow 23 95.7% 22 / 23
Urinary symptoms 86 24.4% 21 / 86
Pain with urination 21 100.0% 21 / 21
Psychologic disturbance 86 16.3% 14 / 86
Dizziness 86 12.8% 11 / 86
Difficult swallow 23 30.4% 7 / 23
Nausea 86 7.0% 6 / 86
Ocular symptoms (pain, redness, visual loss) 86 5.8% 5 / 86
Red eye(s) 5 100.0% 5 / 5
Vomiting 86 4.7% 4 / 86
Chest pain 86 4.7% 4 / 86
Decrease urine output 20 20.0% 4 / 20
Diarrhoea 86 3.5% 3 / 86
Eye pain 5 60.0% 3 / 5
Any rectal symptom 86 2.3% 2 / 86
Urethral discharge 21 9.5% 2 / 21
Rectal pain 2 100.0% 2 / 2
Other 5 20.0% 1 / 5
Proctitis 86 0.0% 0 / 86
Rectal discharge 2 0.0% 0 / 2
Rectal urgency/tenesmus 2 0.0% 0 / 2
Visual disturbance 5 0.0% 0 / 5
...with blood 4 0.0% 0 / 4

Source: WHO
Symptoms at discharge
Variable Sample size Prevalence pct Frequency
Sore throat 81 1.2% 1 / 81
Fever 81 0.0% 0 / 81
Pruritis/itching 80 0.0% 0 / 80
Muscle pain or aching 81 0.0% 0 / 81
Headache 81 0.0% 0 / 81
Ocular symptoms (pain, redness, visual loss) 81 0.0% 0 / 81
Fatigue or malaise 81 0.0% 0 / 81
Pain in mouth 81 0.0% 0 / 81
Nausea 81 0.0% 0 / 81
Vomiting 81 0.0% 0 / 81
Diarrhoea 81 0.0% 0 / 81
Any rectal symptom 81 0.0% 0 / 81
Swallowing problem 81 0.0% 0 / 81
Chest pain 81 0.0% 0 / 81
Joint pain or aching 81 0.0% 0 / 81
Proctitis 81 0.0% 0 / 81
Dizziness 81 0.0% 0 / 81
Psychologic disturbance 81 0.0% 0 / 81
Urinary symptoms 81 0.0% 0 / 81

Source: WHO
Variable

Person with HIV
N = 11

Person without HIV
N = 67

Unknown
N = 8

 p-value 1
age, Median (Q1, Q3) 10.50 (8.00, 12.00) 8.00 (5.00, 9.00) 9.50 (8.00, 10.50) 0.005
    Missing/Unknown 1 0 0
Sex at birth, n (%)


0.077
    Male 5 (45%) 44 (66%) 3 (38%)
    Female 5 (45%) 23 (34%) 5 (63%)
    Intersex 0 (0%) 0 (0%) 0 (0%)
    Unknown 1 (9.1%) 0 (0%) 0 (0%)
Race, n (%)


>0.9
    African/Black 10 (91%) 62 (93%) 8 (100%)
    Arab 0 (0%) 0 (0%) 0 (0%)
    Asian 0 (0%) 0 (0%) 0 (0%)
    Hispanic/Latino 0 (0%) 0 (0%) 0 (0%)
    Mixed Race 0 (0%) 0 (0%) 0 (0%)
    White 0 (0%) 0 (0%) 0 (0%)
    Unknown 1 (9.1%) 5 (7.5%) 0 (0%)
    Other 0 (0%) 0 (0%) 0 (0%)
health care worker, n (%)


0.4
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 10 (91%) 66 (99%) 8 (100%)
    Unknown 1 (9.1%) 1 (1.5%) 0 (0%)
Laboratory worker, n (%)


0.6
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 10 (91%) 64 (96%) 8 (100%)
    Unknown 1 (9.1%) 3 (4.5%) 0 (0%)
Sex worker, n (%)


0.008
    Yes 4 (36%) 2 (3.0%) 1 (13%)
    No 6 (55%) 61 (91%) 7 (88%)
    Unknown 1 (9.1%) 4 (6.0%) 0 (0%)
currently pregnant or was pregnant in the last 6 weeks?, n (%)


>0.9
    Yes 0 (0%) 1 (4.3%) 0 (0%)
    No 5 (100%) 22 (96%) 5 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 6 44 3
Breastfeeding, n (%)



    Yes 0 (NA%) 0 (NA%) 0 (NA%)
    No 0 (NA%) 0 (NA%) 0 (NA%)
    Unknown 0 (NA%) 0 (NA%) 0 (NA%)
    Missing/Unknown 11 67 8
1

Kruskal-Wallis rank sum test; Fisher’s exact test
Variable

Person with HIV
N = 11

Person without HIV
N = 67

Unknown
N = 8

 p-value 1
ever hospitalized, n (%)


0.8
    Yes 8 (89%) 54 (83%) 7 (100%)
    No 1 (11%) 11 (17%) 0 (0%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 2 1
Length of hospitalization, Median (Q1, Q3) 12 (7, 18) 6 (5, 12) 8 (4, 11) 0.13
    Missing/Unknown 3 13 1
Escalation of care, n (%)


0.045
    Yes 1 (13%) 0 (0%) 1 (14%)
    No 7 (88%) 54 (100%) 6 (86%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 3 13 1
supplemental oxygen, n (%)


0.045
    Yes 1 (13%) 0 (0%) 0 (0%)
    No 7 (88%) 54 (100%) 6 (86%)
    Unknown 0 (0%) 0 (0%) 1 (14%)
    Missing/Unknown 3 13 1
receive nasogastric fluids, n (%)


>0.9
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 9 (100%) 65 (100%) 7 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 2 1
receive IV fluids during course monkeypox infection, n (%)


0.017
    Yes 2 (22%) 2 (3.1%) 2 (29%)
    No 7 (78%) 63 (97%) 5 (71%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 2 1
receive analgesia for pain management, n (%)


<0.001
    Yes 7 (78%) 20 (31%) 6 (86%)
    No 2 (22%) 45 (69%) 1 (14%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 2 1
receive antibiotics during course monkeypox infection, n (%)


>0.9
    Yes 8 (89%) 58 (89%) 7 (100%)
    No 1 (11%) 7 (11%) 0 (0%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 2 1
receive antifungals during course monkeypox infection, n (%)


>0.9
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 9 (100%) 65 (100%) 7 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 2 1
experimental antiviral during course monkeypox infection, n (%)


>0.9
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 9 (100%) 65 (100%) 7 (100%)
    Unknown 0 (0%) 0 (0%) 0 (0%)
    Missing/Unknown 2 2 1
1

Fisher’s exact test; Kruskal-Wallis rank sum test
Variable

Person with HIV
N = 11

Person without HIV
N = 67

Unknown
N = 8

 p-value 1
History of tetanus vaccination, n (%)


0.2
    Yes 0 (0%) 7 (10%) 2 (25%)
    No 2 (18%) 25 (37%) 3 (38%)
    Unknown 9 (82%) 35 (52%) 3 (38%)
History of smallpox vaccination before 1980, n (%)


0.6
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 8 (73%) 56 (84%) 7 (88%)
    Unknown 3 (27%) 11 (16%) 1 (13%)
History of smallpox or monkeypox vaccination in past year, n (%)


0.6
    Yes 0 (0%) 0 (0%) 0 (0%)
    No 10 (91%) 62 (93%) 7 (88%)
    Unknown 1 (9.1%) 5 (7.5%) 1 (13%)
Number of vaccines received, Median (Q1, Q3) NA (NA, NA) NA (NA, NA) NA (NA, NA)
    Missing/Unknown 11 67 8
1

Fisher’s exact test
Variable

Person with HIV
N = 11

Person without HIV
N = 67

Unknown
N = 8

 p-value 1
New diagnosis of HIV, n (%)


0.084
    Yes 0 (0%) 1 (1.5%) 1 (14%)
    No 8 (100%) 63 (97%) 5 (71%)
    Unknown 0 (0%) 1 (1.5%) 1 (14%)
    Missing/Unknown 3 2 1
Current new STI (Sexually Transmitted Infection) diagnosis, n (%)



    Yes 0 (0%) 0 (NA%) 0 (NA%)
    No 2 (100%) 0 (NA%) 0 (NA%)
    Unknown 0 (0%) 0 (NA%) 0 (NA%)
    Missing/Unknown 9 67 8
Immunosuppressive condition, n (%)


0.002
    Yes 1 (9.1%) 0 (0%) 0 (0%)
    No 10 (91%) 67 (100%) 6 (75%)
    Unknown 0 (0%) 0 (0%) 2 (25%)
Most recent CD4, Median (Q1, Q3) 98 (98, 98) NA (NA, NA) NA (NA, NA)
    Missing/Unknown 1 67 8
Viral load, n (%)



    Detectable 0 (0%) 0 (NA%) 0 (NA%)
    Undetectable 3 (30%) 0 (NA%) 0 (NA%)
    Unknown 7 (70%) 0 (NA%) 0 (NA%)
    Missing/Unknown 1 67 8
AIDS - defining illness, n (%)



    Yes 0 (0%) 0 (NA%) 0 (NA%)
    No 10 (100%) 0 (NA%) 0 (NA%)
    Unknown 0 (0%) 0 (NA%) 0 (NA%)
    Missing/Unknown 1 67 8
1

Fisher’s exact test
Skin lesions by HIV status
Complications by HIV status
Variable

Confirmed case
N = 44

Not confirmed
N = 36

 p-value 1
HIV status, n (%)

0.001
    Person with HIV 8 (18%) 1 (2.8%)
    Person without HIV 29 (66%) 35 (97%)
    Unknown 7 (16%) 0 (0%)
age, Median (Q1, Q3) 8.00 (8.00, 10.50) 7.00 (5.00, 8.50) 0.008
Sex at birth, n (%)

0.6
    Male 26 (59%) 24 (67%)
    Female 18 (41%) 12 (33%)
    Intersex 0 (0%) 0 (0%)
    Unknown 0 (0%) 0 (0%)
Race, n (%)

>0.9
    African/Black 42 (95%) 34 (94%)
    Arab 0 (0%) 0 (0%)
    Asian 0 (0%) 0 (0%)
    Hispanic/Latino 0 (0%) 0 (0%)
    Mixed Race 0 (0%) 0 (0%)
    White 0 (0%) 0 (0%)
    Unknown 2 (4.5%) 2 (5.6%)
    Other 0 (0%) 0 (0%)
health care worker, n (%)

>0.9
    Yes 0 (0%) 0 (0%)
    No 43 (98%) 36 (100%)
    Unknown 1 (2.3%) 0 (0%)
Laboratory worker, n (%)

0.6
    Yes 0 (0%) 0 (0%)
    No 43 (98%) 34 (94%)
    Unknown 1 (2.3%) 2 (5.6%)
Sex worker, n (%)

0.049
    Yes 6 (14%) 0 (0%)
    No 36 (82%) 34 (94%)
    Unknown 2 (4.5%) 2 (5.6%)
currently pregnant or was pregnant in the last 6 weeks?, n (%)

0.4
    Yes 0 (0%) 1 (8.3%)
    No 18 (100%) 11 (92%)
    Unknown 0 (0%) 0 (0%)
    Missing/Unknown 26 24
Breastfeeding, n (%)


    Yes 0 (NA%) 0 (NA%)
    No 0 (NA%) 0 (NA%)
    Unknown 0 (NA%) 0 (NA%)
    Missing/Unknown 44 36
1

Fisher’s exact test; Wilcoxon rank sum test
Variable

Confirmed case
N = 44

Not confirmed
N = 36

 p-value 1
HIV status, n (%)

0.001
    Person with HIV 8 (18%) 1 (2.8%)
    Person without HIV 29 (66%) 35 (97%)
    Unknown 7 (16%) 0 (0%)
ever hospitalized, n (%)

0.12
    Yes 40 (91%) 28 (78%)
    No 4 (9.1%) 8 (22%)
    Unknown 0 (0%) 0 (0%)
Length of hospitalization, Median (Q1, Q3) 9 (5, 14) 5 (4, 10) 0.020
    Missing/Unknown 4 8
Escalation of care, n (%)

>0.9
    Yes 1 (2.5%) 1 (3.6%)
    No 39 (98%) 27 (96%)
    Unknown 0 (0%) 0 (0%)
    Missing/Unknown 4 8
supplemental oxygen, n (%)

0.7
    Yes 0 (0%) 1 (3.6%)
    No 39 (98%) 27 (96%)
    Unknown 1 (2.5%) 0 (0%)
    Missing/Unknown 4 8
receive nasogastric fluids, n (%)

>0.9
    Yes 0 (0%) 0 (0%)
    No 44 (100%) 36 (100%)
    Unknown 0 (0%) 0 (0%)
receive IV fluids during course monkeypox infection, n (%)

0.2
    Yes 5 (11%) 1 (2.8%)
    No 39 (89%) 35 (97%)
    Unknown 0 (0%) 0 (0%)
receive analgesia for pain management, n (%)

0.003
    Yes 25 (57%) 8 (22%)
    No 19 (43%) 28 (78%)
    Unknown 0 (0%) 0 (0%)
receive antibiotics during course monkeypox infection, n (%)

>0.9
    Yes 40 (91%) 33 (92%)
    No 4 (9.1%) 3 (8.3%)
    Unknown 0 (0%) 0 (0%)
receive antifungals during course monkeypox infection, n (%)

>0.9
    Yes 0 (0%) 0 (0%)
    No 44 (100%) 36 (100%)
    Unknown 0 (0%) 0 (0%)
experimental antiviral during course monkeypox infection, n (%)

>0.9
    Yes 0 (0%) 0 (0%)
    No 44 (100%) 36 (100%)
    Unknown 0 (0%) 0 (0%)
1

Fisher’s exact test; Wilcoxon rank sum test
Variable

Confirmed case
N = 44

Not confirmed
N = 36

 p-value 1
HIV status, n (%)

0.001
    Person with HIV 8 (18%) 1 (2.8%)
    Person without HIV 29 (66%) 35 (97%)
    Unknown 7 (16%) 0 (0%)
History of tetanus vaccination, n (%)

0.8
    Yes 4 (9.1%) 5 (14%)
    No 17 (39%) 12 (33%)
    Unknown 23 (52%) 19 (53%)
History of smallpox vaccination before 1980, n (%)

>0.9
    Yes 0 (0%) 0 (0%)
    No 37 (84%) 31 (86%)
    Unknown 7 (16%) 5 (14%)
History of smallpox or monkeypox vaccination in past year, n (%)

0.7
    Yes 0 (0%) 0 (0%)
    No 40 (91%) 34 (94%)
    Unknown 4 (9.1%) 2 (5.6%)
Number of vaccines received, Median (Q1, Q3) NA (NA, NA) NA (NA, NA)
    Missing/Unknown 44 36
1

Fisher’s exact test
Variable

Confirmed case
N = 44

Not confirmed
N = 36

 p-value 1
HIV status, n (%)

0.001
    Person with HIV 8 (18%) 1 (2.8%)
    Person without HIV 29 (66%) 35 (97%)
    Unknown 7 (16%) 0 (0%)
New diagnosis of HIV, n (%)

0.7
    Yes 2 (4.7%) 0 (0%)
    No 40 (93%) 35 (97%)
    Unknown 1 (2.3%) 1 (2.8%)
    Missing/Unknown 1 0
Current new STI (Sexually Transmitted Infection) diagnosis, n (%)


    Yes 0 (0%) 0 (NA%)
    No 2 (100%) 0 (NA%)
    Unknown 0 (0%) 0 (NA%)
    Missing/Unknown 42 36
Immunosuppressive condition, n (%)

0.5
    Yes 0 (0%) 0 (0%)
    No 42 (95%) 36 (100%)
    Unknown 2 (4.5%) 0 (0%)
Most recent CD4, Median (Q1, Q3) 98 (98, 98) 98 (98, 98) >0.9
    Missing/Unknown 36 35
Viral load, n (%)

>0.9
    Detectable 0 (0%) 0 (0%)
    Undetectable 3 (38%) 0 (0%)
    Unknown 5 (63%) 1 (100%)
    Missing/Unknown 36 35
AIDS - defining illness, n (%)

>0.9
    Yes 0 (0%) 0 (0%)
    No 8 (100%) 1 (100%)
    Unknown 0 (0%) 0 (0%)
    Missing/Unknown 36 35
1

Fisher’s exact test; Wilcoxon rank sum test
Skin lesions by mpox status
Complications
Exposure distribution
Variable Sample size Prevalence pct Frequency
Sexually active within ≤ 21 days prior to symptom onset? 86 44.2% 38/86
Number of heterosexual partners in the last three months 37 78.4% 29/37
Any known link to probable or confirmed case of monkeypox within ≤ 21 days prior to symptom onset? 86 10.5% 9/86
International travel within ≤ 21 days prior to symptom onset? 86 4.7% 4/86
Contact with possible animal source within ≤ 21 days prior to symptom onset? 86 0.0% 0/86
Did the patient receive experimental antiviral during course monkeypox infection? 81 0.0% 0/81

Source: WHO
Variable N = 86
Mpox clade known:, n (%)
    Yes 0 (0%)
    No 81 (100%)
    Unknown 0 (0%)
    Missing/Unknown 5
Mpox clade, n (%)
    Ia 0 (NA%)
    Ib 0 (NA%)
    IIa 0 (NA%)
    IIb 0 (NA%)
    Missing/Unknown 86
Monkeypox PCR, n (%)
    Yes 80 (99%)
    No 1 (1.2%)
    Unknown 0 (0%)
    Missing/Unknown 5
Monkeypox Result, n (%)
    Positive 44 (55%)
    Negative 34 (43%)
    Indeterminate 0 (0%)
    Unknown 2 (2.5%)
    Missing/Unknown 6
Monkeypox viral culture, n (%)
    Yes 0 (0%)
    No 81 (100%)
    Unknown 0 (0%)
    Missing/Unknown 5
Monkeypox viral culture Result, n (%)
    Positive 0 (NA%)
    Negative 0 (NA%)
    Indeterminate 0 (NA%)
    Unknown 0 (NA%)
    Missing/Unknown 86
Variable N = 86
Orthopoxvirus PCR, n (%)
    Yes 0 (0%)
    No 81 (100%)
    Unknown 0 (0%)
    Missing/Unknown 5
Orthopoxvirus Result, n (%)
    Positive 0 (NA%)
    Negative 0 (NA%)
    Indeterminate 0 (NA%)
    Unknown 0 (NA%)
    Missing/Unknown 86
Variable N = 86
Malaria result, n (%)
    Positive 0 (0%)
    Negative 5 (100%)
    Indeterminate 0 (0%)
    Unknown 0 (0%)
    Missing/Unknown 81
Syphilis result, n (%)
    Positive 1 (50%)
    Negative 1 (50%)
    Indeterminate 0 (0%)
    Unknown 0 (0%)
    Missing/Unknown 84
Variable

Baseline visit
N = 86
Hemoglobin, Median (Q1, Q3) 12.80 (11.10, 15.30)
WCC total, Median (Q1, Q3) 6.9 (6.4, 11.1)
Platelets, Median (Q1, Q3) 254 (156, 319)
PT, Median (Q1, Q3) NA (NA, NA)
APTT, Median (Q1, Q3) NA (NA, NA)
Total Bilirubin, Median (Q1, Q3) NA (NA, NA)
ALT, Median (Q1, Q3) NA (NA, NA)
AST, Median (Q1, Q3) NA (NA, NA)
Na+, Median (Q1, Q3) NA (NA, NA)
K+, Median (Q1, Q3) NA (NA, NA)
Urea/BUN, Median (Q1, Q3) NA (NA, NA)
Creatinine, Median (Q1, Q3) NA (NA, NA)
Glucose, Median (Q1, Q3) NA (NA, NA)
Lactate, Median (Q1, Q3) NA (NA, NA)
CRP, Median (Q1, Q3) NA (NA, NA)
Creatine kinase, Median (Q1, Q3) NA (NA, NA)
Variable

During infection management
N = 184
Hemoglobin, Median (Q1, Q3) 12.60 (11.10, 15.90)
WCC total, Median (Q1, Q3) 6.8 (5.1, 10.4)
Platelets, Median (Q1, Q3) 255 (156, 332)
PT, Median (Q1, Q3) NA (NA, NA)
APTT, Median (Q1, Q3) NA (NA, NA)
Total Bilirubin, Median (Q1, Q3) NA (NA, NA)
ALT, Median (Q1, Q3) NA (NA, NA)
AST, Median (Q1, Q3) NA (NA, NA)
Na+, Median (Q1, Q3) NA (NA, NA)
K+, Median (Q1, Q3) NA (NA, NA)
Urea/BUN, Median (Q1, Q3) NA (NA, NA)
Creatinine, Median (Q1, Q3) NA (NA, NA)
Glucose, Median (Q1, Q3) NA (NA, NA)
Lactate, Median (Q1, Q3) NA (NA, NA)
CRP, Median (Q1, Q3) NA (NA, NA)
Creatine kinase, Median (Q1, Q3) NA (NA, NA)
Variables Lab measures distribution
N Mean Median Min Max Distribution
Baseline visit
Hemoglobin 18.00 13.12 12.80 6.30 18.00
Platelets 18.00 264.94 253.50 71.00 731.00
WCC total 17.00 8.84 6.90 3.00 29.00
Outcomes